Revance Therapeutics (RVNC)
(Delayed Data from NSDQ)
$5.81 USD
-0.04 (-0.68%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $5.83 +0.02 (0.34%) 7:38 PM ET
2-Buy of 5 2
D Value B Growth NA Momentum NA VGM
Income Statements
Fiscal Year end for Revance Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 234 | 133 | 78 | 15 | 0 |
Cost Of Goods | 74 | 52 | 23 | 5 | 0 |
Gross Profit | 160 | 81 | 54 | 11 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 476 | 423 | 329 | 284 | 165 |
Income After Depreciation & Amortization | -317 | -342 | -275 | -273 | -164 |
Non-Operating Income | 12 | 3 | 0 | 4 | 5 |
Interest Expense | 19 | 16 | 6 | 15 | 0 |
Pretax Income | -324 | -356 | -281 | -285 | -159 |
Income Taxes | 0 | 1 | 0 | -3 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -324 | -356 | -281 | -282 | -159 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -324 | -356 | -281 | -282 | -159 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -214 | -303 | -253 | -254 | -164 |
Depreciation & Amortization (Cash Flow) | 103 | 39 | 21 | 20 | 0 |
Income After Depreciation & Amortization | -317 | -342 | -275 | -273 | -164 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 84.60 | 72.71 | 67.51 | 58.01 | 43.46 |
Diluted EPS Before Non-Recurring Items | -3.83 | -4.90 | -4.17 | -4.86 | -3.67 |
Diluted Net EPS (GAAP) | -3.83 | -4.90 | -4.17 | -4.86 | -3.67 |
Fiscal Year end for Revance Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 65.39 | 51.94 | 69.80 | 56.78 | 58.13 |
Cost Of Goods | 17.64 | 14.91 | 17.47 | 19.41 | 21.31 |
Gross Profit | 47.75 | 37.03 | 52.33 | 37.36 | 36.83 |
SG&A, R&D, and Dept/Amort Expenses | 82.27 | 83.85 | 29.11 | 176.65 | 102.33 |
Income After SG&A, R&D, and Dept/Amort Expenses | -34.52 | -46.82 | 23.22 | -139.29 | -65.50 |
Non-Operating Income | 2.73 | 2.56 | 3.65 | 3.51 | 2.55 |
Interest Expense | 5.68 | 5.26 | 5.40 | 5.09 | 4.37 |
Pretax Income | -37.47 | -49.53 | -55.70 | -140.88 | -67.32 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.30 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -37.47 | -49.53 | -55.70 | -141.18 | -67.32 |
Extras & Discontinued Operations | 0.00 | -3.63 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -37.47 | -53.15 | -55.70 | -141.18 | -67.32 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 103.87 | 91.92 | 90.15 | 86.61 | 83.69 |
Diluted EPS Before Non-Recurring Items | -0.36 | -0.54 | -0.62 | -0.74 | -0.80 |
Diluted Net EPS (GAAP) | -0.36 | -0.58 | -0.66 | -1.63 | -0.80 |